« Return to News | CROs/Service Providers

Charles River Labs to Open Preclinical Facility in Shanghai

Wednesday, October 15, 2008 12:41 PM

Preclinical research powerhouse Charles River Laboratories is expanding its global reach with a new 60,000-square-foot facility in Shanghai, China.

Slated to open in early 2009, the new facility will support a growing demand from multinational pharmaceutical clients for outsourced drug development services, according to a Charles River release.

“As our clients make their initial forays into China, we are creating a center of excellence that embodies global best practices alongside them,” said James Foster, president, chairman and CEO of Charles River. “Our clients have come to appreciate and rely on the expertise Charles River brings to their drug development efforts, and the convenience of our facilities in close proximity. The same high standards of research, safety, humane care and good laboratory practices that globally distinguish Charles River are replicated in our Shanghai facility. Expanding into this arena is a marathon—not a sprint—and this facility marks the first step in our journey.”

In March 2007, Charles River announced a joint venture with Shanghai BioExplorer, a Shanghai-based provider of preclinical services, to form Charles River Preclinical Services Greater China.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.